Q2 2025 · 13F-HR
CAXTON CORPholdings as filed
Filed 2025-08-14 · accession 0000919574-25-004762
$9.9M
Reported value
11
Positions
2025-06-30
Period end
The Brief · CAXTON CORP · Q2 2025
AI · grounded in 13F
CAXTON CORP established a new position in RZLT valued at $7.15M. The fund also initiated new holdings in GLD for $1.51M and BRK/B for $307K. Other new additions include ELVN, BRD1EUR, and CMPX.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76200L309 | RZLT | REZOLUTE INC | $7.2M | 72.6% | 1,603,986 | Common | SOLE |
| 78463V107 | GLD | SPDR GOLD TR | $1.5M | 15.3% | 4,952 | Common | SOLE |
| 084670702 | BRK/B | BERKSHIRE HATHAWAY INC DEL | $307,040 | 3.12% | 632 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $262,736 | 2.67% | 13,097 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $221,134 | 2.24% | 34,073 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $113,010 | 1.15% | 43,465 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $101,643 | 1.03% | 10,941 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $70,552 | 0.72% | 22,981 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $69,674 | 0.71% | 17,332 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $31,966 | 0.32% | 16,393 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $12,058 | 0.12% | 18,403 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.